throbber
Bacteria and gut immunity
`
`Shobha Char, PhD, and Michael J.G. Farthing, MD, FRCP
`
`The Medical College of St. Bartholomew's Hospital, London, UK
`
`The interaction between the intestinal microflora and the host
`mucosal im mune system is complex. Intestina l bacteria are considered
`vital for the maturatio n and maintenance of intestinal immunity in
`healthy individuals but may have harmful effects when the flo ra
`is modified by d rugs such as the proton p ump inhibitors, wh ich
`suppress gastric acid. Research continues to support the concept that
`a healthy flora can be maintained by certain bacterial species suc h
`as Lactobacillus, although their therapeutic role in disease states has
`not yet been estab lished. Translocatio n of bacteria across the gut
`wall occurs in certain d isease states in which epithelial integrity is
`disrupted, particularly during intravenous nutrition and small bowel
`transplantation. Impairment of mucosal imm unity has recently been
`documented in HIV infection and AI DS, including a deficit in antige n
`presentation. Modulatio n of gut immune responses is the cornerstone
`of vaccine development for intestinal infections. New antige n delivery
`systems are being developed that may assist in promoting protective
`immune responses rather than the development of oral tolerance.
`
`Current Opinion in Gastroenterology 1994, 10:659-663
`
`Intestinal microflora
`
`The human gastrointestinal tract contains 1014 bacte(cid:173)
`rial cells (an equivalent of 1 kg). There is a marked
`variation in the n umber and pattern of bacterial flora
`at different levels of the tract. The number of ingested
`bacteria is reduced dramatically by gastric acid. A low
`concentration of organisms is maintained in the small
`bowel by intestinal motility that ensures that nonadher(cid:173)
`ent organisms are constantly cleared from the small in(cid:173)
`testine. Despite this clearing, the concentration of bac(cid:173)
`teria increases from the jejunum through the ileum,
`with a marked increase in the colon. The bacterial
`content of duodenal fluid following acid inhibition by
`the p roton pump inhibitor omeprazole was examined
`in a controlled prospective study (1 •]. Duodenal bac(cid:173)
`terial overgrowth of both oral- and fecal-type bacte(cid:173)
`ria occurred frequently in ambulatory patients treated
`with omeprazole. Further studies are needed to deter(cid:173)
`mine the clinical significance during long-term treat(cid:173)
`ment with omeprazole. Shin do et a/. (2•) found evi(cid:173)
`dence of overgrowth of bacteria capable of deconjugat(cid:173)
`ing bile salts in the jejunum of seven of 27 patients with
`liver cirrhosis who had a positive bile acid breath test.
`Bacterial overgrowth in these patients was attributed to
`the sh ift to alkaline pH in the gastric juice.
`
`The dominant populations of bacteria in the intes(cid:173)
`tine are members of the genera Bacteroides, Eubac-
`
`terium, Bifidobacterium, Clostridium, Lactobactllus,
`and Fusobacterium. Escherichia coli and aerotoler·
`ant streptococci constitute the accompanying flora.
`Various microorganisms are eliminated from the in(cid:173)
`testine by a "barrier effect" exerted by the normal
`microflora. The normal microflora thus supports the
`immune system by providing colonization resistance
`against pathogenic exogenous microorganisms. Lacto(cid:173)
`bacillus sp has been shown to inhibit the growth of
`potentially pathogenic organisms such as Staphylococ(cid:173)
`cus, Pseudomonas, Salmonella, and Helicobacter py(cid:173)
`lori in vitro. It has been suggested that Lactobacil(cid:173)
`lus migh t contribute to the maintenance of coloniza(cid:173)
`tion resistance through the production of lactic and
`acetic acids, hydrogen peroxide, and antimicrobial sub(cid:173)
`stances. It is thus considered important to maintain the
`levels of Lactobacillus in the intestinal flora because
`several other studies also indicate a protective effect
`against potential pathogens (3••].
`
`Bacterial translocation
`
`In normal situations, the only bacteria that readily
`transloc:ate from the intestinal lumen to mesenteric
`lymph nodes (MLNs) and other viscera are facultative
`intr.tcellular pathogens such as Salmonella spp and Lis(cid:173)
`teria spp. It is well known that this tendency is in(cid:173)
`creased in patients with impaired T-cell function, such
`
`Abbreviations
`GVHD-graft-versus-host disease; MLN- mesenteric lymph node; TNF- tumor necrosis factor.
`
`© 1994 Current Science ISBN 1-85922-611·6 ISSN 0267- 1379
`
`659
`
`

`

`660
`
`Immunology
`
`as those with AIDS or lymphomas, or organ transplant
`recipients. Lim et at. [4•) studied the effect of HIV in(cid:173)
`fection on intestinal lamina propria macrophage sub(cid:173)
`sets in 4I patients at various stages of HIV infection.
`The results show that there was no difference in over(cid:173)
`all density of macrophages, but there was a significant
`decrease in dendritic cells in all clinical stages of HIV.
`Thus, the antigen-presenting arm of mucosal immune
`defenses may be seriously compromised in HIV infec(cid:173)
`tion, and this loss represents a further insult to mucosal
`immunity already impaired as a result of loss of CD4+
`T lymphocytes. These factors may contribute to the de(cid:173)
`velopment of opportunistic infection in the gut.
`
`In the context of mechanisms involved in immune re(cid:173)
`sponse, bacterial translocation through specialized ab(cid:173)
`sorptive cells, called M cells, appears to be a part of the
`antigen-sampling process resulting in the development
`of gut-associated lymphoid tissue [5). The term bacte(cid:173)
`rial translocation has been used to describe the pas(cid:173)
`sage of bacteria from the gut lumen through the mu(cid:173)
`cosa to the MLNs and other organs. The main factors
`promoting bacterial translocation include virulence and
`pathogenicity of the bacterial strain, increased numbers
`of the bacterial strain in the gut because of disturbances
`in the indigenous intestinal microflora, permeability of
`the intestinal mucosa, and a lowered immune status of
`the host.
`
`Translocation has not been shown directly in healthy
`individuals. However, tf"anslocation enables contact of
`bacteria or bacterial fragments with the immune system
`and consequently leads to the production of systemic
`antibacterial antibodies. Indeed such antibodies have
`been detected in healthy individuals directed against
`their own anaerobic fecal bacteria [6) and a facultatively
`anaerobic E. coli strain that colonized the gastrointest(cid:173)
`inal tract after oral ingestion [7]. Apperloo-Renkema
`et a/. [8••) demonstrate a decrease in the coloniza(cid:173)
`tion resistance of intestinal microflora in patients with
`the autoimmune disease systemic lupus el)'thematosus.
`A lower colonization resistance theoretically increases
`the risk of translocation of more bacterial species,
`which may trigger the polyclonal and antigen-specific
`B-cell activation that leads to the production of multi(cid:173)
`ple autoantibodies in systemic lupus erythematosus.
`
`Bacterial translocation has been identified as a possible
`mechanism for the development of sepsis in various
`experimental conditions and in surgery, obstructive
`jaundice, acute pancreatitis, and burn patients. Runkel
`et al. [9-l examined the hypothesis that prolonged in(cid:173)
`testinal transit time may disrupt the luminal microflora
`of the gut and thereby promote bacterial translocation
`in an animal model. Following administration of mor(cid:173)
`phine, which is known to inhibit bowel transit, sam(cid:173)
`ples were obtained from the MLNs, blood, spleen, liver,
`duodenum, jejunum, ileum, and cecum for standard
`bacteriology. The bacterial counts increased signifi(cid:173)
`cantly in each intestinal segment following morphine
`treatment. Bacteria translocated to the MLNs in five,
`and to distant sites in four of eight morphine-tested
`
`animals. The authors concluded that the morphine-in(cid:173)
`duced prolongation in bowel transit promotes bacte(cid:173)
`rial translocation secondary to an overgrowth of en(cid:173)
`teric bacteria in the intestinal lumen. Thus, bacterial
`overpopulation of the bowel is an important promoter
`of translocation. Further studies are needed to deter(cid:173)
`mine whether therapeutic stimulation of motility might
`be a possible means of managing sepsis and whether
`the use of drugs that slow bowel motility are clinically
`important in the pathogenesis of sepsis. Price et a/.
`[lo••J assessed the effects of rejection, graft-versus-host
`disease (GVHD) and immunosuppression after hetero(cid:173)
`topic small bowel transplantation in rats. Isografts, al(cid:173)
`lografts with and without immunosuppression, and the
`semiallogenic parent to the Fl hybrid GVHD model
`were studied. Intestinal microflora in graft and host
`loops and bacterial translocation to host organs and
`the graft MLNs were determined. Bacterial tr.ansloca(cid:173)
`tion was not detected in isografted animals, but was
`observed in all other animal groups. These data show
`that bacterial translocation from the intestine occurs in
`the presence of acute rejection and GVHD and that
`immunosuppression to prevent rejection does not pre(cid:173)
`vent translocation.
`
`Bacterial lipopolysaccharide has been speculated to fa(cid:173)
`ciLitate bacterial translocation by a mechanism involv(cid:173)
`ing physical disruption of the gut mucosal barrier. Wells
`eta/. [II••) used polarized, cultured intestinal epithelial
`cells (Caco2 cells) to study the effect of lipopolysaccha(cid:173)
`ride on emerocyte structure, viability, and susceptibility
`to bacterial invasion and found no discernible effect.
`Thus, lipopolysaccharide-induced bacterial transloca(cid:173)
`tion might not involve loss of epithelial viability or fa(cid:173)
`cilitated entry of bacteria into intestinal epithelial cells.
`
`Nord [I2] has reviewed the ecologic effects of peni(cid:173)
`cillins, cephalosporins, macrolides, tetracyclines, ni(cid:173)
`troimidazoles, and quinolines on the human intestinal
`microflor.a. The disturbances in normal intestinal mi(cid:173)
`c roflora can cause bacterial overgrowth and emergence
`of resistant microorganisms, which may lead to serious
`infections and also encourage transfer of resistance fac(cid:173)
`tors among bacteria.
`
`Intestinal immune system
`
`The intestine is the largest immune organ in the body.
`It has been estimated that gut-associated lymphoid tis(cid:173)
`sue contains 400/0 of the immune effector cells in the
`body, possibly representing up to 25% of the intesti(cid:173)
`nal mucosal mass. Intestinal immune cells are found
`in one of three compartments: as aggregates in folli(cid:173)
`cles and Peyer's patches, distributed within the mu(cid:173)
`cosa as diffuse elements of the lymphoid network, and
`in the epithelium [I3l. Various interleukins and other
`cytokines that contribute to interactions among cellu(cid:173)
`Ear components of the immune system are produced
`by cells within the lamina propria. Conversely, cellu(cid:173)
`Ear constituents of the lamina propria mucosae have
`been found to respond to various cytokines. Pang et al.
`
`

`

`Bacteria and gut immunity Char and Farthing
`
`661
`
`(14•] reported the presence of interleukin-2-activated
`large granular lymphocytes in the lamina propria of
`human duodenal mucosa that secrete an array of cy(cid:173)
`tokines and may thus regulate cells of myeloid and
`monocytic lineages. The intestinal epithelium is where
`the host encounters a myriad of different environmen(cid:173)
`tal antigens and pathogens. A number of recent re(cid:173)
`ports demonstrate that intestinal epithelial cells are a
`potentially important source of a number of cytokines
`that may modulate the immune response at the in(cid:173)
`testinal mucosa. Intestinal epithelial cell populations
`have been found to express or respond to interleukin-
`1, interleukin-2 (15•), interleukin-6 (16•], tumor necro(cid:173)
`sis factor (TNF), interferon-"( , and transforming growth
`factor-PU5•]. Nicholls et al. [17•] have shown that there
`is a constant low-grade production of TNF-o. in the in(cid:173)
`testines of healthy people and attribute this produc(cid:173)
`tion to the possible leaking of antigenic products of
`the normal flora across normal epithelium, leading to
`continual stimulation of the intestinal immune system.
`Using immunohistochemistry, they have documented
`cells containing TNF-o. the subepithelial lamina pro(cid:173)
`pria mucosae of colonic biopsy specimens from chil(cid:173)
`dren with no detectable gut disease [18•].
`
`The use of cytokines in nonspecific therapy of bacte(cid:173)
`rial infections has been reviewed by Vogels and van der
`Meer (19). Administrc:ltion ofTNF-o. or interleukin-1 and
`interleukin-6 to mice before infection with Salmonella
`typhimurium and Listeria monocytogenes, respec(cid:173)
`tively, protected them from an otherwise lethal infec(cid:173)
`tion. Interferon-"( inhibits the replication of L. mono(cid:173)
`cytogerws in hepatocytes [20•]. Baqar et a/. [21•] have
`shown that orally administered cytokines interleukin-
`2, interleukin-5, or interleukin-6 offered protection in
`mice challenged with Campylobacter jejuni. Although
`the mechanism involved in developing such immuniry
`is not yet known, the oral administration of cytokines
`could minimize many of the problems associated with
`the systemic administration of these molecules.
`
`Mucosal vaccines
`
`Secretory lgA represents the primary immune bar(cid:173)
`rier against pathogens. Gut-associated lymphoid tis(cid:173)
`sue secretes 40 mg/kg body weight of IgA daily, com(cid:173)
`pared with 30 mg/kg of IgG produced by the to(cid:173)
`taJ immune system. Intestinal B cell activation, al(cid:173)
`though quite variable after oral cholera vaccination,
`is in the rank order IgA, IgG, and IgM. Nilssen
`et al. [22•) report that in IgA-deficient individuals,
`IgG antibodies are elicited as compensation for the
`impaired IgA response following oral cholera vac(cid:173)
`cination. Although
`the vaccine might be of im(cid:173)
`portance for enhancing mucosal immunity in IgA(cid:173)
`deficient individuals, the authors caution that in pa(cid:173)
`tients with chronic gut disease it could enhance IgG(cid:173)
`mediated immunopathology in the absence of anti(cid:173)
`inflammatory IgA antibodies.
`
`Many groups are currently working on the develop(cid:173)
`ment of enteric vaccines for the prevention of both
`
`intestinal and systemic infections. McGhee et at. [23•]
`have reviewed areas that are currently receiving ex(cid:173)
`tensive research attention and will be of major impor(cid:173)
`tance for development of mucosal and systemic immu(cid:173)
`nity following oral vaccination. The use of delivery sys(cid:173)
`tems such as biodegradable microspheres incorporat(cid:173)
`ing an array of antigens is reviewed by Elridge et a/.
`[24•]. Orr eta/. [25•) evaluated an acellular approach to
`induce type-specific anti-Shigella immunity using the
`proteosome delivery system. Proteosomes are prepa(cid:173)
`rations of neissarial outer membrane protein vesicles
`that have previously been shown to enhance the par(cid:173)
`enteral immunogenicity of peptides. Their new candi(cid:173)
`date vaccine for shigellosis was composed of Shigella
`lipopolysaccharide complexed with proteosome. Their
`data demonstrate that proteosomes can be used as
`an effective mucosal vaccine delivery system and that
`orally or intranasally administered acellular vaccines
`can protect against Shigella infections. Hornquist and
`Lycke [26•] demonstf"c:~te that cholera toxin given orally
`as an adjuvant with antigen-promoted antigen priming
`of both the helper T-cell subsets Thl and Th2 of CD4+
`T precursor cells. Further information will no doubt
`be forthcoming in the next few years regarding opti(cid:173)
`mal mucosal vaccine delivery systems and protocols for
`mucosal immunization.
`
`References and recommended reading
`
`Papers of particular interest, published within the annual period of
`review, have been highlighted as:
`Of special interest
`Of outstanding interest
`
`••
`
`1.
`
`Fried M, Siegrist H, Feci R. Froehlich F. Duroux P, Thorens
`), Blum A, Bille G. Convers n. Cyr K: Duodenal Bacterial
`Overgrowth During Treatment With Omeprazote. Gut 1994.
`35:23-26.
`The extent of bacterial overgrowth during the profound inhibition of acid
`secretion that occurs with omeprazole treatment is unknown. This con(cid:173)
`trolled prospective study examined the bacterial content of duodenal as(cid:173)
`pirates of patients treated with omeprazole. The results indicate that duo(cid:173)
`denal bacteria l overgrowth of both fecal and oral type bacteria occurs
`often in ambulatory patient~ treated with omeprazole.
`2.
`Shindo K. Machida M. Miyakawa K, f'ukumura M: A Syndrome
`of Cirrhosis, Achlorhydria. Small Intestinal Bacterial Overgrowth,
`amd Fat Malabsorption. Am} Gastroemero/ 1993, 88:2084-2091.
`Twenry-s.:ven patients with liver cirrhosis, tested by a breath analysis
`technique using glycine-J-14C- Iabeled glycocholate. showed a marked
`increase of t·1C02-specific activity. Bacterial overgrowth was found in the
`jejunal fluid of these patients. The majority of the bacterial species that
`were identified deconjugated bile acids. There was a good correlation
`between t1COz a~;ivity and gastric pH. The authors conclude that some
`patients with liver cirrhosis have bacterial overgrowth in the proxima l
`small imestine. which is probably associated with the shift to alkaline pH
`in gastriC' juice.
`3.
`Lidbeck A, Nord CE: l..actobacilli and the: Normal Human Anaer-
`obic Microflora. Clir1 Infect Dis 1993, 16:Sl8J-s187.
`The normal human micronora is a complex and usually stable ecosystem.
`Administrntion of antimicrobial agents may disrupt the normal microflora,
`leading to a decrease in colonization resistance. lactobacilli are part or
`the normal gram-positive anaerobic microflora. Several studies have in(cid:173)
`dicated the protective effect of lactobacilli against potential pathogens in
`the gastrointestinal tract. Thus, it is considered important to maintain or
`increase their levels in the intestinal micronora.
`4.
`Lim SG, Condez A, Poulter LW: Mucosal Macrophage Subsets
`of the Gut in Hrv: Decrease in Anligen·Presenting l'hcnorype.
`Clfn F.xp Immunol 1993, 92:442-447.
`
`

`

`662
`
`Immunology
`
`6.
`
`7.
`
`8.
`
`The aim of this study was to investigate alterations in macrophage sub(cid:173)
`populations in patients at different stages of HIV disease and their rele(cid:173)
`vance to the associated decrease in mucosal immunity. The result sug(cid:173)
`gests that the antigen-presenting arm of mucosal immune defenses may
`be seriously compromised in HIV infection.
`5.
`Wells CL, Maddaus MA, Simmons RL: Proposed Mechanisms for
`the Translocation of Intestinal Bacteria. Rev Infect Dis 1988,
`10:958-978.
`Apperloo-Renkema HZ, Wilkinson MFH, van der Waaij 0 :
`Circulating Antibodies Against Faecal Bacteria Assessed by
`lmmunomorphometry: Combining Quanlltuive lmmunolluores(cid:173)
`cen~ and Image Analysis. Epidemiollnfect 1992, 109:497-506.
`Apperloo-Renkema HZ, van der Waaij 0 : Study of Coloniza(cid:173)
`tion Resistance for Enterobacterlauae in Man by Experimental
`Contamination and Biocyping as WeU as the Possible Role of An(cid:173)
`tibodies in the Clearance of These Bacteria From the Intestines.
`Epidemiol Infect 1991, 107:619-626.
`Apperloo-Renkema HZ, Bootsma H. Mulder AI, Kallenberg CG,
`van der Waaij D: Host-Microllora Interaction in Systemic Lupus
`Erythematosus (systemic lupus erythematosus): Colonizallon Re(cid:173)
`sistance of the Indigenous Bacteria of the Jnt~-stinal Tract. Epi(cid:173)
`demiol Infect 1994, 112:367-373.
`There is increasing evidence that in autoimmune disease-prone animals,
`the composition of the indigenous intestinal micronora might play an im(cid:173)
`portant role in the expression of autoimmune disorders. In this study, col(cid:173)
`onization resistance (the defense capacity of the indigenous micronora
`against colonization of the intestines by foreign bacteria) was measured
`in healthy individuals and patients with the autoimmune disease systemic
`lupus erythematosus by a comprehensive biotyping technique. coloniza(cid:173)
`tion resistance tended to be lower in patients with active systemic lupus
`erythematosus than in healthy individuals. The authors suggest that this
`difference could indicate that, in systemic lupus erythematosus, more and
`different bacteria translocate across the gut wall, some of which could
`serve as polydonal B-cell activators or as antigens cross reacting with
`DNA.
`9.
`
`Runkel NSf, Moody fG, Smith GS, Rodriguez Lf, Chen Y,
`Larocco MT, Miller TA: Alterations in Rat Intestinal Transit by
`Morphine Promote Bacterial Translocation. Dig Dis Sci 1993.
`38:1530-1536.
`This study examined the role of altered bowel transit in influencing in(cid:173)
`testinal bacteriostasis and bacterial translocation using morphine as a
`pharmacologic inhibitor of transit and concluded that the morphine-in(cid:173)
`duced prolongation in bowel transit promotes baCterial translocation sec(cid:173)
`ondary to an overgrowth of enteric bacteria in the intestina l lumen.
`10.
`Price BA, Cumberland NS, Ingham Clark CL. Pockley AG, Lear
`••
`PA, Wood RFM: The EffeCt of Rejection and Graft-Versus-Host
`Disease on SmaU Intestinal Mlcroflora and Bacterial Translo(cid:173)
`cation After Rat SmaU Bowel Transplantation. Transplantation
`1993. 56:1072--1076.
`The effects of rejection, GVHD, and immunosuppression on intestinal
`microflora and bacterial translocation after heterOtropic rat small bowel
`transplantation were assessed in this study. The results demonstr-Jte that
`rejection and G VHD are associated with shifts in intestinal micro nora to(cid:173)
`ward potentially pathogenic organisms and that bacterial translocation
`into recipient tissues poses a major threat for the development of sep(cid:173)
`sis.
`
`11. .. Wells CL, jechorek RP, Olmsted SB. Erlandsen SL: Eff~'<:t of
`
`LPS on EpitheUal Integrity and BaCterial Uplalce in the Polar·
`ized Human Enterocyte·Uke Cell Une Caco2. Ctrc Shock 1993.
`40:276-288.
`Bacterial lipopolysaccharide has been speculated to facilitate bacterial
`translocation by a mechanism involving physic-dl disruption of the gut
`mucosal barrier. Using a polarized. cultured intestinal epithelial cell line
`(Caco2), this study demonstrated that lipopolysaccharide-induced bacte(cid:173)
`rial translocation might not involve loss of epithelial viability or facilitated
`entry of bacteria into intestinal epithelial cells.
`Nord C: The Effect of Antinticrobial Agents on the Ecology of
`12.
`the Human Intestinal Microflora. Vet Mtcrobfol1993, 35:193-197.
`Kagnoff MF: Immunology of the Intestinal Tract. Gastroenterol(cid:173)
`ogy 1993. 105:1275-1280.
`Pang G, Buret A, Batey RT, Chen QY, Couch L. Cripps A, Clancy
`R: Morphological, Phenotypic and Functional Characteristics of a
`Pure Population of CDS6+ CD16-CD3- Large Granular Lympho(cid:173)
`cytes Generated From Human Duodenal Mucosa. Jmmur1ology
`19')3, 79:498-505.
`
`13.
`
`14.
`
`This study has shown for the first time that CD56+ CDI6-CD3-large gran(cid:173)
`ular lymphocytes can be generated from histologically normal duodenal
`mucosa by culturing the biopsy-obtained tissue in the presence of recom·
`binant interleukin-2. These cells may be related to classic NK cells and
`rna y produce an array of cytokines and direct cytotoxJcity against rumor
`cells. The results provide evidence for an important role of gut mucosal
`large granular lymphocytes in the induction and regulation of inflamma·
`lion and immunity in the gut.
`15.
`Ciacci C, Mahida YR, Koizumi M, Podolsky DK: Functional
`lmer!eu.kln-2 Receptors on Intestinal EpltheUal CeUs. 1 Gin In·
`vest 1993, 92:527-532.
`This paper repons the presence of intermediate- and low-affinity func(cid:173)
`tional receptors for the cytokine interleukin·2 in the JEC-6 cell line es(cid:173)
`tablished from normal crypt epithelium. The relevance of observations
`in the IEC-6 cell line to intestinal mucosa In vivo was supported by the
`demonstration of a gradient of expression of the interleukin-2 receptor
`in primary rat intestinal epithelial cells. These results suggest that the
`range of cellular targets of interleukin·2 is broader than appreciated, and
`interleukin-2 may serve to integrate epithelial and lymphocyte responses
`in the intestinal mucosa.
`16. McGee OW, Beagley KW, Aicher WK, McGhee JR: lfansfonnlng
`Growth Facto~ and JL.Ij} Act in Synergy to Enhance IL6 Se(cid:173)
`<.:n:tion by the Intestinal Epithelial Cell Une, IEC-6. 1 Jmmunol
`1993. 151:970-978.
`The regulation of interleukin-6 secretion by intestinal epithelial cells was
`studied using the IEC-6 cell line as a model. lnterleukin·l was found to be
`a potent inducer of interleukin-6 secretion by the IEC-6 cell line. Trans(cid:173)
`forming growth factor-P and interleukin-11} aCt in synergy to enhance
`interleukin-6 secretion by the IEC-6 cell line. These results suggest that
`the intestinal epithelial cell may be an important interleukin-6 producing
`cell in mucosal immune responses.
`Nicholls S, Stephens S, Braegger CP, Walker-smith J, Macdonald
`17.
`•
`TT: Cytokines in Stools of ChUdren with Inflammatory Bowel
`Disease or Infective Diarrhoea. 1 Clln Pathol 1993, 46:757-760.
`l11e concentrations of interleukin-6 and TNF-« were measured in feces
`from 14 healthy children, 32 children with inflammatory bowel disease,
`and 2~ 9lildren with ac;vt\! diarrhea. TNF-a was detected in the stools of
`aU healthy children. Raised values of TNF-a were indicative of mucosal
`inflammation, but were not specific. Stool interleukin-6 was of little use
`in assessing mucosal inflammation because immunoreactivity is rapidly
`lost in stool samples.
`18. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT: Loca·
`lion of TNF<t Immunohistochemistry in Cluonic Inflammatory
`Bowel Disease. Gut 1993, 34:1705-1709.
`The location and tissue density of cells immunoreactive for TNF-« in in(cid:173)
`testinal specimens from 24 patients with chronic inflammatory bowel dis(cid:173)
`ease was studied. There was increased density of TNF-a immunoreactive
`cells in the lamina propria mucosae of both ulcerative colitis and Crohn's
`disease specimens that might contribute to the pathogenesis of these dis(cid:173)
`eases.
`19.
`
`Vogels MTI;, van der Meer JWM: Use of Immune Modulators in
`Nonspecific Therapy of Bacterial Infections. Anlimtcrob Agents
`Cbemother 1992, 36:1-5.
`IFN-r Inhibits
`the Replication of
`Gregory SH. Wing EJ:
`Listeria monocytogenes in Hepatocytes. 1 lmmunol 1993,
`151:1401-1409.
`Hepatocytes constitute the principal site of listerial replication in the liv(cid:173)
`ers of nonimmune mice whereas in immune mice the bacteria are rapidly
`eliminated. This paper repons that interferon gamma produced during
`primary infection-5 exens a significant inhibitory effect on the replication
`of Listeria within the parenchymal cells of the liver. In vitro experiments
`indicate that interferon gamma-stimulated hepatocytes possess the ele·
`vated capacity to kill intracellular Listeria organisms.
`21.
`Baqar S, Pacheco NO, Rollwagen FM: Modulation of Mucosal
`Immunity Against Campylobacter jejunt by Orally Administered
`Cytoltines. Anlimlcrob Agents Cbemother 1993, 37:2688-2692.
`l11is is the first report of a study in which animals were given oral cy-
`tokines and challenged with an enteric pathogen. Using a murine model
`of infeCtion, the authors found enhanced clearance of bacteria and in(cid:173)
`creased C. jejuni-speciftc serum and secretory immunoglobulin levels af·
`ter oral cytokine feeding. The data presented suggest that interleukin-2,
`interleukin-5, and interleukin-6 may each have different roles or func(cid:173)
`tions in the induction and subsequent regulation of protective immune
`responses.
`Nilssen DE, Friman v, Theman K, Bjorkander J, Kilander A,
`22.
`Holmgren J, Hanson LA, Brandtzaeg P: 8-Cc:U Activation in Duo(cid:173)
`denal Mucosa After Oral Cholera Vaccination in lgA Defident
`
`20.
`•
`
`

`

`Bacteria and gut immunity Char and Farthing
`
`663
`
`Sub~ctS With or Without lgG Subclass lkficlcncy. Scand j Jm(cid:173)
`munol 1993. 38:201-208.
`Aher:uions in duodenal immunoglobulin·producing cells induced by IWO
`cholera 112ccines were 51\Jdied in mucosal tissue sec~ ions from adultS with
`selective lgA deficiency. The results showed that oral cholera 112ccination
`preferentially aCtivates imestinallgG·produdng cells in these subjects and
`that lgG rather than lgM antibodies are elicited as compensation for a
`lacking lgA response.
`McGhee JR, fujihashi K, Xu-Amano J, jackson RJ, Elson CO,
`23.
`•
`Beagley KW, Kiyono H: New Perspectives in Mucosal Immunity
`With Emphasis on Vaccine lkvelopment. Semitl Hematol 1993.
`30:~15.
`111e focus in this review is on five areas that arc currently receiving exten(cid:173)
`sive research anention and will be of major importance for development
`of mucosal and systemic immunity to oral vaccines. These five areas in(cid:173)
`clude the following: helper T cell subsets (Th) and cytokines for mucosal
`lgA responses, Thl· and Th2-type subsets in regulation of mucosal lgA
`responses, antigen uptake and presentation in the mucosal immune sys(cid:173)
`tem, the importanCe of memory in mucosal immunity to vaccines, and
`the determination of whether oral immuni:z:~tion alone induces immunity
`In all mucosal effector tissues.
`Elridge JH, Staas JK, Chen 0 , Marx PA. Tice TR. Gilley RM:
`24.
`New Advances in Vaccine lkUvery Systems. Semin HetMto/
`1993, 30:16-24.
`This review focuses on the usc of microspheres composed of the
`biodegradable and biocompatiblc copolymer poly DL-Iactide-co-glycol(cid:173)
`lde as a promising approach to the delivery of vaccines, combining ad(cid:173)
`juvant activity with controlled release and effective presentation to mu(cid:173)
`cosally associated lymphoid tissues.
`2S. Orr N. Robin G. Cohen D. Arnon R, Lowell GH: lmmunogenlc-
`lty and Efficacy of Oral or Intranasal Sblgelkl jlexnerl 2a and
`•
`
`SblgeUa sonnel Proteosome-Upopolysaccharide Vaccines In An·
`imal Modef5. Infect Immun 1993. 6 1:239(}-2395.
`A new acellular candidate vaccine for shigellosis composed of purified
`Shigella flexneri 2a and Sbi[Jelkl sonnei lipopolysaccharide hydrophobi·
`cally complexed with group C type 2b Neisseria meningitidEs outer mem(cid:173)
`brane protein proceosomes has been tested. Immunization of mice either
`orally or intranasally with this complex Induced specific homologous anti(cid:173)
`lipopolysaccharide antibodies in both inteslinal and respiratory secretions
`as well as in sera. These data demoru.trdtc: that proleosomes can be used
`as an effective mucosal vaccine: delivery system.
`
`26.
`
`Hornquist E, t.ycke N: Cholera Toxin Adjuvant Greatly Promotes
`Antigen Priming ofT C-c:Us. Eur j lmmutw/1993, 23:2136-2143.
`11liS study was undertaken to investigate If cholera toxi.n administered
`together with keyhole limpet hemocyanin would aet to promote or in(cid:173)
`hibit priming of keyhole limpet hemocyanin-specific T cells and whether
`1hc adjuvant effect of cholera toxin is strictly an effect on intestinal anti(cid:173)
`gen processing or is a generalized phenomenon. The results clearly show
`that cholera toxin adjuvant SIIQngly promotes antigen-specific priming of
`C04• T lymphocytes. The adjuvant effect of cholera toxin was not re(cid:173)
`striCted to mucosal immune responses but was also evident following
`a single parenteral immuniZation with keyhole limpet hemocyanin and
`cholera toxin.
`
`Shobha Char, PhD, and Michaci].G. Fanhing, MD, FRCP, The Medical
`College of St. Banholomew's Hospital, Digestive Diseases Research
`Centre, Charterhouse Square, London ECIM 6BQ, UK.
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket